Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 18/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8140858 | 0.91 | ELANE (0.61) | ELANECYP2C9CYP3A4 | |
| SCHEMBL1764340 | 0.90 | ELANE (0.60) | ELANECYP2C9CYP3A4 | |
| SCHEMBL3482663 | 0.88 | ELANE (0.72) | ELANECYP2C9CYP3A4 | |
| SCHEMBL14796910 | 0.88 | ELANE (0.57) | ELANECYP2C9CYP3A4 | |
| SCHEMBL2888375 | 0.85 | ELANE (0.69) | ELANECYP2C9CYP3A4MAPT | |
| SCHEMBL392232 | 0.85 | ELANE (1.00) | ELANECYP2C9CYP3A4 | |
| SCHEMBL1764353 | 0.85 | ELANE (1.00) | ELANECYP2C9CYP3A4 | |
| SCHEMBL3482731 | 0.85 | ELANE (1.00) | ELANECYP2C9CYP3A4 | |
| SCHEMBL9914374 | 0.84 | ELANE (0.71) | ELANECYP2C9CYP3A4MAPT | |
| SCHEMBL2895205 | 0.83 | ELANE (0.69) | ELANECYP2C9CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580800-B2 | 1,4-diaryl-pyrimidopyridazine-2,5-diones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580800-B2 | 1,4-diaryl-pyrimidopyridazine-2,5-diones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580800-B2 | 1,4-diaryl-pyrimidopyridazine-2,5-diones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| EP-2285809-B1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER IP GMBH (DE) | 2013-03-27 | — | — | EP | disclosed |
| US-20110118221-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118221-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118221-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-19 | — | — | US | disclosed |
| WO-2009135599-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118221-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | QDPR, DPYD, DPP4 | ELANE 1816/4885CYP2C9 1333/4885CYP3A4 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.